



## TETRATHERIX ASX IPO

Tetratherix Limited (ASX:TTX) is pleased to announce the official listing of its shares on the Australian Securities Exchange (ASX), marking a significant milestone in the company's evolution and future growth trajectory.

The listing represents the beginning of a new chapter for Tetratherix as it transitions to a publicly listed company with a clear purpose: to accelerate the development and commercialisation of its proprietary polymer platform to improve patient outcomes across a wide range of clinical indications.

Tetratherix extends its sincere thanks to its long-standing shareholders for their continued support and welcomes its new investors who have joined the company on this journey. From inception, Tetratherix has been guided by a strong belief in the potential of its materials science platform to address real-world clinical needs.

Will Knox (TTX CEO): "ASX listing has always been on our journey as a business, our near term growth trajectory and commercial momentum make this the right time. On behalf of our leadership team, we would like express our gratitude to all of our staff, investors and partners who have all played a role in helping us reach this exciting milestone."

This IPO is not an endpoint or an exit strategy. It is a foundation upon which Tetratherix will accelerate product development, expand its global clinical footprint and scale manufacturing and commercial operations.

### Looking Ahead

Tetratherix enters this next phase with a strong sense of purpose, responsibility and resolve. The company's platform is well-positioned to drive a new wave of innovation across multiple clinical disciplines, and the capital raised through the IPO will be instrumental in scaling its global impact. The company thanks its shareholders and partners for their support as it embarks on this next stage of growth.

**MEDIA RELEASE**

30 JUNE 2025

**Capital Structure****Securities on issue**

Ordinary shares	27,110,055
Ordinary shares on conversion of preference shares	9,480,550
Total (on issue)	36,590,605

**Securities issued**

IPO Offer	8,680,000
Ordinary shares on conversion of convertible notes	3,807,270
Ordinary shares on conversion of SAFE Notes.	1,253,762
Total Securities Issued <sup>1</sup>	13,741,032
Grand Total	50,331,637

Note 1: Securities have been issued.

**ASX Mandatory Escrow**

No of Shares	Restriction Period
23,570,766	Until 30 June 2027, being 24 months from the date of quotation
14,059	Until 2 September 2025, being 12 months from the date of issue
28,117	Until 6 September 2025, being 12 months from the date of issue
101,571	Until 6 December 2025, being 12 months from the date of issue
2,190	Until 20 December 2025, being 12 months from the date of issue
18,951	Until 20 June 2026, being 12 months from the date of issue

**Voluntary Escrow**

No of Shares	Restriction Period
500,000	Until 3 months from quotation
1,491,740	Until 6 months from quotation
5,950,638	Until 4:15pm on the trading day after the date on which the Company releases to the ASX its financial results for the half year ended December 2025
5,950,629	Until 4:15pm on the trading day after the date on which the Company releases to the ASX its financial results for the half year ended June 2026

< ENDS >

For further information / to arrange an interview contact:  
Matthew Wright  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

<https://tetratherix.com/>

